David Collingridge/LinkedIn
Jul 5, 2025, 04:23
David Collingridge: This Year’s Impact Factor of The Lancet Oncology
David Collingridge, Editor-in-Chief at The Lancet Oncology, shared on LinkedIn:
“Every year, journals around the world receive different metrics to reflect their performance. While only a limited measure of our impact, I am pleased to share that The Lancet Oncology has an Impact Factor of 35·9 and a Scopus CiteScore of 50·8.
Congratulations to our authors and peer reviewers, whose expertise and hard work enable us to continuously publish some of the best science for better lives.
You can access our full reach and impact statement, including additional measures of our global reach and high impact, here.”
More Posts Featuring The Lancet Oncology.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 1, 2025, 19:24
Aug 1, 2025, 19:14
Aug 1, 2025, 18:32